ctDNA assays are quickly finding their way into the clinic. These assays have a potential role to play in all phases of the cancer continuum because they answer various clinical questions (Figure 1). Their use is moving up to earlier-stage settings from their initial development and approval for patients with metastatic cancer. As these agents enter more prominent clinical use, it is vital for clinicians to understand that there are different kinds of ctDNA assays.